Long-term risk of medical conditions associated with breast cancer treatment

Breast Cancer Research and Treatment

Volumn 145, Issue 1, 2014, Pages 233-243

  Hill, Deirdre A ^a   Horick, Nora K ^b   Isaacs, Claudine ^d   Domchek, Susan M ^e   Tomlinson, Gail E ^f   Lowery, Jan T ^g   Kinney, Anita Y ^a   Berg, Jonathan S ^h   Edwards, Karen L ⁱ   Moorman, Patricia G ^j   Plon, Sharon E ^l   Strong, Louise C ^k   Ziogas, Argyrois ^m   Griffin, Constance A ⁿ   Kasten, Carol H ^o   Finkelstein, Dianne M ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

^g Food Science and Human Nutrition   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY OF TEXAS   (United States)

^l BAYLOR COLLEGE OF MEDICINE   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

more..

Author keywords

Breast neoplasms; Chemotherapy; Heart disease; Lymphedema; Osteoporosis; Radiotherapy

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HEART DISEASE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LYMPHEDEMA; MAJOR CLINICAL STUDY; OSTEOPENIA; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TUMOR INVASION; BONE DISEASES, METABOLIC; BREAST NEOPLASMS; HEART DISEASES; LYMPH NODE DISSECTION; MIDDLE AGED; QUESTIONNAIRE; RADIOTHERAPY; STATISTICS AND NUMERICAL DATA; SURVIVOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE DISEASES, METABOLIC; BREAST NEOPLASMS; FEMALE; HEART DISEASES; HUMANS; LYMPH NODE EXCISION; LYMPHEDEMA; MIDDLE AGED; OSTEOPOROSIS; PREVALENCE; QUESTIONNAIRES; RADIOTHERAPY; RISK FACTORS; SURVIVORS;

EID: 84900469750     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2928-4     Document Type: Article

References (31)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E (2012) Cancer treatment and survivorship statistics. CA Cancer J Clin 62(4):220-241. doi: 10.3322/caac.21149
2. Dictionary of Cancer Terms. http://www.cancer.gov/dictionary?cdrid= 390292. Accessed 14 Sept 2013
3. Norman SA, Localio AR, Kallan MJ, Weber AL, Torpey HA, Potashnik SL, Miller LT, Fox KR, DeMichele A, Solin LJ (2010) Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiol Biomarkers Prev 19(11):2734-2746. doi: 10.1158/1055-9965
4. Ahmed RL, Schmitz KH, Prizment AE, Folsom AR (2011) Risk factors for lymphedema in breast cancer survivors, the Iowa Women's Health Study. Breast Cancer Res Treat 130(3):981-991. doi: 10.1007/s10549-011-1667-z
5. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D (2008) Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26(12):1948-1955. doi: 10.1200/JCO.2007.11.6798
6. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26(7):1051-1057. doi: 10.1200/JCO.2007.11.0726
7. Winters-Stone KM, Schwartz AL, Hayes SC, Fabian CJ, Campbell KL (2012) A prospective model of care for breast cancer rehabilitation: bone health and arthralgia. Cancer 118(8 Suppl):2288-2299. doi: 10.1002/cncr.27465
8. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10:337. doi: 10.1186/1471-2407-10-337
9. Russell SD, Blackwell KL, Lawrence J, Pippen JE Jr, Roe MT, Wood F, Paton V, Holmgren E, Mahaffey KW (2010) Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 28(21):3416-3421. doi: 10.1200/JCO.2009.23.6950
10. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25(25):3808-3815. doi: 10.1200/jco.2006.10.4976
11. Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS (2008) Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. J Clin Oncol 26(8):1223-1230. doi: 10.1200/JCO.2007.11. 8877
12. Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS (2005) Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97(6):419-424. doi: 10.1093/jnci/dji067
13. Darby SC, McGale P, Taylor CW, Peto R (2005) Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6(8):557-565. doi: 10.1016/S1470-2045(05)70251-5
14. Bonneterre J, Roche H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, Montcuquet P, Clavere P, Barats JC, Monnier A, Veyret C, Datchary J, Van Praagh I, Chapelle-Marcillac I (2004) Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 22(15):3070-3079. doi: 10.1200/JCO.2004.03.098-22/15/3070
15. Petrek JA, Senie RT, Peters M, Rosen PP (2001) Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 92(6):1368-1377. doi: 10.1002/1097-0142(20010915)92:6<1368:aid-cncr1459>3.0.co;2-9
16. McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 26(32):5213-5219. doi: 10.1200/JCO.2008.16. 3725
17. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S (1996) Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14(1):78-84
18. Vehmanen L, Elomaa I, Blomqvist C, Saarto T (2006) Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 24(4):675-680. doi: 10.1200/JCO.2005.02.3515
19. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453):60-62. doi: 10.1016/S0140-6736(04) 17666-6
20. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8(2):119-127. doi: 10.1016/S1470-2045(07)70003-7
21. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL (2005) Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 23(34):8597-8605. doi: 10.1200/JCO.2005.02. 5841
22. Anton-Culver H, Ziogas A, Bowen D, Finkelstein D, Griffin C, Hanson J, Isaacs C, Kasten-Sportes C, Mineau G, Nadkarni P, Rimer B, Schildkraut J, Strong L, Weber B, Winn D, Hiatt R, Nayfield S (2003) The Cancer Genetics Network: recruitment results and pilot studies. Commun Genet 6(3):171-177
23. Gupta V, Gu K, Chen Z, Lu W, Shu XO, Zheng Y (2011) Concordance of self-reported and medical chart information on cancer diagnosis and treatment. BMC Med Res Methodol 11:72. doi: 10.1186/1471-2288-11-72
24. Phillips KA, Milne RL, Buys S, Friedlander ML, Ward JH, McCredie MR, Giles GG, Hopper JL (2005) Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry. J Clin Oncol 23(21):4679-4686. doi: 10.1200/JCO.2005.03.002
25. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ (2004) Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 57(10):1096-1103. doi: 10.1016/j.jclinepi. 2004.04.005
26. Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B, Hennekens CH, Speizer FE (1986) Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol 123(5):894-900
27. Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, Miller LT, DeMichele A, Solin LJ (2009) Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol 27(3):390-397. doi: 10.1200/jco.2008.17.9291
28. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104(17):1293-1305. doi: 10.1093/jnci/djs317
29. Harris EE, Correa C, Hwang WT, Liao J, Litt HI, Ferrari VA, Solin LJ (2006) Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 24(25):4100-4106. doi: 10.1200/JCO.2005.05.1037
30. Bouillon K, Haddy N, Delaloge S, Garbay JR, Garsi JP, Brindel P, Mousannif A, Le MG, Labbe M, Arriagada R, Jougla E, Chavaudra J, Diallo I, Rubino C, de Vathaire F (2011) Long-term cardiovascular mortality after radiotherapy for breast cancer. J Am Coll Cardiol 57(4):445-452. doi: 10.1016/j.jacc.2010.08.638
31. Roychoudhuri R, Robinson D, Putcha V, Cuzick J, Darby S, Moller H (2007) Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer 7:9. doi: 10.1186/1471-2407-7-9